USA flag logo/image

An Official Website of the United States Government

Antihormonal to Leukemia--Modified Cytokine Receptor

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
24863
Program Year/Program:
1995 / SBIR
Agency Tracking Number:
24863
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
PROED, INC.
9290 GAITHER RD GAITHERSBURG, MD 20877
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 1995
Title: Antihormonal to Leukemia--Modified Cytokine Receptor
Agency: HHS
Contract: 1 R43 CA63861-1,
Award Amount: $692,768.00
 

Abstract:

This Phase I is designed to test feasibility of developing immunotoxins for human lymphoidleukemia using IL-2 and either 90Y or 131I. There is ample evidence that many cases of humanleukemia are cytokine-dependent. The Principal Investigator has long experience in the study oferythropoietin-dependent erythroleukemia induced by Friend's spleen focus forming virus. Recently,several clinical trials have already established the efficacy of immunotoxin approach in certainmalignancies and other diverse conditions such as autoimmune disorders and graft vs. host diseases.In this application, we will test bioactivity of human recombinant prepare and purify 131I-IL-2, prepareand purify 90Y-IL-2, analyze the radiolabeled IL-2 compounds and test specificity of the compoundsusing cell lines that are dependent on other cytokines. We will also test the effects on primary murineand human T-cells.

Principal Investigator:

David Hankins
3016522130

Business Contact:

Small Business Information at Submission:

Proed, Inc.
4853 Cordell Avenue #1407 Bethesda, MD 20814

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No